
· Executive Brief
Blood Cancer Awareness Month 2026
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Leadership signal
Recognition becomes useful when leaders inspect the real route.
The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Blood cancer care is a referral and handoff problem as much as a treatment problem
Blood cancers rarely announce themselves with a single clear sign. They often surface as an abnormal blood count, a vague symptom or a skin finding that is first read as something benign. That is why the route from first abnormal result to a specialist decision deserves executive attention. When that route is slow, unclear or overloaded, delay accumulates before treatment has a chance to work.
Recent research shows how much of this delay sits inside the delivery system. In a Tanzanian cohort of children with acute lymphoblastic leukemia, the median time from symptom onset to arrival at the national hospital was 28.5 days.[2] A median of 14 more days then passed before diagnosis.[2] In four academic hospitals in Madrid, 18,190 patients were referred for a first hematology appointment for complaints included in an automated test-ordering initiative.[1] Volume of that size makes referral design a capacity question, not only a clinical one.
Specialized diagnostics and therapies add another layer. A 2026 review of inequities in hematologic cancer care named limited access to hematopathology, flow cytometry, cytogenetic and molecular testing as major diagnostic barriers.[4] A separate review of chimeric antigen receptor (CAR) T-cell therapy described high cost and demanding implementation requirements that widen existing access gaps.[5]
This section adds the evidence base behind the operating guidance already on this page. It covers burden, diagnostic routes, laboratory capacity, transplant and cellular therapy access, patient experience and equity. The aim is to help leaders ask where their own system loses time and trust, and what they can measure to know whether it is improving. Most of the studies are small or come from settings outside the United States. They are offered as signals for local inquiry, not as performance targets.
Current evidence
What recent studies show about burden, risk and diagnostic routes
Population data help leaders anticipate demand rather than react to it. A Swedish nationwide cohort followed 7,156 patients with polycythemia vera, 6,810 with essential thrombocythemia and 1,080 with primary myelofibrosis diagnosed from 2001 to 2021.[9] At a diagnosis age of 70, the 10-year cumulative incidence of acute myeloid leukemia was 3.5%, 4.7% and 18.2% across those three groups.[9] The authors found that risk depended on both age and disease duration, which they call essential for individualized risk assessment.[9]
The same cohort showed that timing differs by subtype. In primary myelofibrosis, leukemia rates were highest soon after diagnosis and declined over time, while in the other two subtypes they rose with disease duration.[9] For myelodysplastic syndromes, the matching 10-year cumulative incidences were 1.7%, 3.1% and 10.7%.[9] Surveillance programs therefore need capacity for both early review and long-horizon follow-up, and they need registries that can tell the two apart.
Environmental exposure research also shapes prevention conversations with communities. A French national case-control study compared 2,731 children with acute leukemia diagnosed from 2008 to 2013 with 28,303 population controls.[15] Most children, 69%, lived less than 1,000 m from crops at diagnosis or inclusion.[15] Two agricultural neighborhood profiles were associated with higher risk of lymphoblastic leukemia, with odds ratios of 1.35 and 1.28.[15] These are associations from observational data, and the authors call for research on the specific chemicals applied to crops.[15]
Diagnostic routes are where operations and outcomes meet. In the Tanzanian cohort, 51.6% of children first sought care at primary-level facilities, while only 18.8% were referred from secondary-level facilities.[2] Six-month and 12-month survival probabilities were 79% and 72%, and most deaths occurred during early treatment.[2] The authors linked improvement to stronger referral systems, supportive care and infection control.[2]
Some studies test whether a routine laboratory value changes the path. In 104 patients with chronic-phase chronic myeloid leukemia followed for a median of 42 months, the molecular marker level at diagnosis did not predict response or prognosis.[13] In 65 Egyptian patients with acute promyelocytic leukemia treated from 2008 to 2017, 20% had hepatitis C infection at diagnosis.[14] Infected patients had a median overall survival of 1 month, compared with 79.3 months in those without infection.[14]
Taken together, the evidence points to a pattern. Risk is predictable enough to plan for, yet the time between first contact and confirmed diagnosis remains the stage most exposed to system design. Several of these studies are small, single-center or drawn from other countries. Their value for U.S. executives lies in the questions they raise about local routes, not in direct benchmarks.
Figure 1
Where patients enter and what they carry: selected hematology pathway findings
Percent of patients in each study population, as reported in each abstract. Values are copied from the cited studies [1], [2], [3], [6], [7]; none is estimated.
Data note. These values come from different studies, countries, populations and denominators, so this is an indirect comparison; only the two Tanzanian bars share a cohort.
Limitation. Each value reflects its own setting and design; none is a benchmark for a U.S. health system.
Figure data (6 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Children who first sought care at primary-level facilities | 51.6% | 64 children with acute lymphoblastic leukemia, Muhimbili National Hospital, Tanzania, 2024 | [2] |
| Children referred from secondary-level facilities | 18.8% | Same cohort of 64 children | [2] |
| Clonal hematopoiesis clinic referrals from primary care | 31.7% | 126 consecutive adult referrals, one large academic health system, 2021 to 2023 | [3] |
| Participants discharged at first hematology visit with a plan | 23.9% | 146 of 612 participants in an automated test-ordering initiative, four academic hospitals in Madrid | [1] |
| Newly diagnosed patients with moderate-to-severe post-traumatic stress symptoms | 33% | 68 patients with newly diagnosed acute leukemia or lymphoma | [6] |
| Patients with chronic lymphocytic leukemia reporting at least one sexual function symptom | 66% | 59 adults, cross-sectional survey, mean 8 years from diagnosis | [7] |

Continuum of care
Where the continuum breaks between referral, diagnosis, treatment and survivorship
The first handoff is from primary care to hematology. In the Madrid study, referral notes were classified with natural language processing, and standardized test orders were placed before the first appointment for participating patients.[1] Of those participants, 146, or 23.9%, were discharged back to primary care at the first visit with a diagnosis and treatment plan.[1] Participants showed a significantly higher rate of first-visit discharge than non-participants, which the authors described as a reduction in avoidable follow-up.[1]
Referral volume also comes from many directions. An academic clonal hematopoiesis clinic reviewed 126 consecutive adult referrals made from 2021 to 2023.[3] Primary care accounted for 31.7% of referrals, hematologists for 23.8% and genetic counselors for 17.5%.[3] Among referrals for low blood counts, two-thirds carried pathogenic variants on targeted sequencing, often changing the working diagnosis.[3] The authors call for standardized referral strategies across specialties.[3]
The next handoff runs from diagnosis to definitive therapy. In 33 adults with T-cell prolymphocytic leukemia who underwent allogeneic transplant, 5-year progression-free survival was 29% and 5-year overall survival was 41%.[8] The 5-year cumulative incidence of relapse was 53%, and immune recovery after transplant was relatively slow in the 22 patients analyzed.[8] Univariable analysis linked a longer time from diagnosis to transplant with improved progression-free survival, with a hazard ratio of 0.36.[8] This is a univariable association in a small single-center series, not guidance on timing.[8] Results like these show why transplant programs need long follow-up pathways, not only a procedure slot.
Survivorship is the least visible stage of the continuum. Among 59 adults with chronic lymphocytic leukemia, a mean of 8 years from diagnosis, sexual activity fell from 93% at diagnosis to 71% at survey.[7] In that survey, 66% reported at least one sexual function symptom, yet interest in formal counseling was limited.[7] The authors recommend routine clinician-initiated discussion, which places the responsibility on the care team rather than the patient.[7]
Between diagnosis and survivorship sits the treatment period, when infection risk is high. In the Tanzanian cohort, most deaths occurred during early treatment, and the authors emphasized supportive care, early complication management and infection control.[2] That finding places inpatient units, emergency departments and infection teams squarely inside the blood cancer continuum. Each of these handoffs has a different owner, and each can fail quietly. Leaders can ask who holds the patient between the abnormal result and the first hematology decision, and again between treatment and long-term follow-up.
Figure 3
Why the pathway breaks
People
- Limited navigation and psychosocial staffing at diagnosis
- Survivorship topics left to patients to raise
- Specialist expertise concentrated in few centers
Process
- Referrals arrive without tests needed for a first-visit decision
- Referral criteria differ across specialties
- Long intervals before arrival at a specialist center
Technology
- Digital referral tools used less by older patients
- New assays without validation or ordering routes
- Non-culture infection tests with limited evidence
Environment
- Travel distance to transplant and cellular therapy centers
- Practical burdens such as transportation and childcare
- Primary-level facilities as first contact
Policy
- High cost and complex requirements for CAR T-cell therapy
- Limited access to transplant in resource-constrained settings
- Administrative barriers to program participation
Measurement
- Time to diagnosis not tracked end to end
- Equity gaps not reported by age or distance
- Outcomes such as treatment delay and abandonment not measured
Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients with possible blood cancer wait too long between an abnormal result and a specialist decision, and lose support after treatment Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [7], [10]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Limited navigation and psychosocial staffing at diagnosis; Survivorship topics left to patients to raise; Specialist expertise concentrated in few centers |
| Process | Referrals arrive without tests needed for a first-visit decision; Referral criteria differ across specialties; Long intervals before arrival at a specialist center |
| Technology | Digital referral tools used less by older patients; New assays without validation or ordering routes; Non-culture infection tests with limited evidence |
| Environment | Travel distance to transplant and cellular therapy centers; Practical burdens such as transportation and childcare; Primary-level facilities as first contact |
| Policy | High cost and complex requirements for CAR T-cell therapy; Limited access to transplant in resource-constrained settings; Administrative barriers to program participation |
| Measurement | Time to diagnosis not tracked end to end; Equity gaps not reported by age or distance; Outcomes such as treatment delay and abandonment not measured |
Access
Laboratory capacity, infection diagnostics and cellular therapy access
Access in hematology depends heavily on laboratory and pathology capacity. The 2026 inequities review identified limited hematopathology, flow cytometry, cytogenetic and molecular testing, residual disease assessment and specialized imaging as major diagnostic barriers.[4] It described tiered diagnostic networks, shared-care models and selective telemedicine as ways to extend that capacity.[4] The review also noted that the supporting evidence is largely observational.[4]
Rare diseases test the limits of local expertise. A study of soluble podoplanin in acute promyelocytic leukemia compared consecutive patients at an academic hospital with 35 matched patients with other forms of acute myeloid leukemia.[12] Levels were significantly higher in the promyelocytic group, which the authors framed as proof of concept for a plasma test that could support diagnosis.[12] For executives, the operational point is that new assays still need validation, a laboratory home and a clear ordering route.
Infection diagnostics are another capacity question. A European expert review of non-culture tests in hematology patients with febrile neutropenia retained only 8 of 293 articles, or 2.7%, on multiplex polymerase chain reaction testing.[10] For T2 magnetic resonance testing, the single retained study reported sensitivity of 84.2% and specificity of 85.9%.[10] No test showed a significant impact on overall survival or length of stay, and the group advised continued routine blood cultures.[10] In 80 children with newly diagnosed acute leukemia, median proadrenomedullin rose from 0.03 nmol/L at diagnosis to 0.41 nmol/L during febrile neutropenia.[11] That signal is promising, but it remains a single-center finding.
Cellular therapy is the clearest example of access shaped by infrastructure. The CAR T-cell review described regulatory, infrastructure, investment, geographic and social barriers to wider use, with added limits in pediatric settings.[5] It highlighted academic partnerships and lower-cost product development as routes to broader access.[5] Community and academic centers in the United States face versions of the same questions about referral timing, travel and payer approval.
An access review can therefore start with three practical checks. Leaders can ask which tests require a send-out, how long results take, and which referral sources wait longest for transplant or cellular therapy evaluation. The answers usually sit in different systems owned by the laboratory, the cancer center and patient access teams. Bringing them into one view is often the first real improvement. It also shows whether delays cluster in particular clinics, payers or days of the week.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Navigate across services
Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Navigate across services | Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Equity gaps follow resources, age, distance and practical burden
Inequity in blood cancer care is often a resource problem before it is a clinical one. The 2026 inequities review documented delayed access to effective therapies, limited use of risk-adapted protocols and inadequate access to transplant and cell therapy.[4] It recommended patient navigation and evaluation against outcomes such as treatment delay, abandonment, toxicity, cost and survival.[4] Those outcome measures give equity committees something concrete to track.
Digital tools can widen or narrow gaps depending on who uses them. In the Madrid referral initiative, participants were significantly younger than non-participants.[1] Only 122 patients expressed explicit unwillingness to take part, and administrative reasons were the most common motive for non-participation.[1] The authors stressed strategies aimed at older patients to improve participation.[1]
Practical burden shapes the experience of diagnosis itself. In 68 patients newly diagnosed with acute leukemia or lymphoma, 33% reported moderate-to-severe post-traumatic stress symptoms.[6] Transportation, childcare, work or school demands, financial issues and recent bereavement were identified as risk factors beyond age, gender and diagnosis.[6] These are social needs that a health system can screen for and address, rather than personal traits.
Resource gaps also shape which treatments reach patients. The inequities review described quality-assured generics and biosimilars, resource-adapted protocols and shared-care models as practical ways to expand access.[4] The CAR T-cell review added that pediatric settings face unique implementation limits.[5] Both reviews describe collaboration, through shared-care models or academic partnerships, as a route to wider access.[4][5] For a U.S. system, that can mean formal referral and co-management agreements between community programs and academic transplant centers.
Geography also matters. In the Tanzanian cohort, the authors concluded that delays in presentation and referral remain significant barriers to care.[2] The CAR T-cell review similarly named geographic and social disparities as barriers to cellular therapy in resource-constrained settings.[5] Rural and distant patients in any country face a version of this travel and referral gap.
Trust grows when patients can see that the system has a plan for these barriers. Leaders can review whether hematology access, test turnaround and therapy referral rates are reported by age, distance, payer and language. The inequities review cautioned that evidence on cost-effectiveness, scalability and survival benefit remains limited.[4] Local measurement is therefore part of the equity work itself.

Human infrastructure
The people and teams that keep hematology pathways moving
Hematology pathways rely on a wide network of roles. The clonal hematopoiesis clinic study showed referrals arriving from primary care, hematology, genetic counseling, oncology and gastroenterology.[3] The authors concluded that multidisciplinary engagement is central to early detection and to standardized referral.[3] That finding argues for shared referral criteria owned jointly by primary care and hematology leaders.
Primary care clinicians remain the main entry point and need support to act on abnormal results. In the Madrid initiative, the referral note itself became the trigger for standardized testing before the specialist visit.[1] The diagnosis of hematologic disorders ruled out was among the ten most common specialist diagnoses for all but one presenting complaint.[1] This suggests that structured pre-visit testing can help specialists use first appointments for decisions rather than information gathering.
Psychological support belongs in the core team. The study of newly diagnosed acute leukemia and lymphoma recommended systematic psychological screening at diagnosis to improve patient-centered hematology care.[6] The chronic lymphocytic leukemia survey found that sexual health concerns were common yet under-addressed, and called for clinicians to start the conversation.[7] Both findings point to nurse navigators, social workers and psychologists as essential roles, not optional extras.
Specialized laboratory and infection teams carry quiet but heavy loads. The European infection review emphasized that newer non-culture tests should be used alongside routine microbiology until better data exist.[10] Laboratory leaders, infection specialists and hematologists therefore need a shared plan for test selection and interpretation. The inequities review likewise lists tiered diagnostic networks among its resource-adapted strategies.[4]
Capacity outside specialist centers matters as much as capacity inside them. The Tanzanian authors called for building early detection capacity at lower-level health facilities.[2] Genetic counselors made 17.5% of referrals to the clonal hematopoiesis clinic, a reminder that new roles now feed hematology demand.[3] Education for these referring teams is a workforce investment that shortens the route to diagnosis. Workforce planning for blood cancer care should include these roles explicitly. Leaders can ask whether navigation, psychosocial screening and laboratory expertise are staffed to current referral volume, or only to the volume of a past year. They can also ask which of these roles have backup coverage when a single expert is away.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Navigation continuity
Where does ownership become unclear as people move among information, evaluation, services, and follow-through?
- Candidate local measure
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Navigation continuity | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Navigation continuity | Where does ownership become unclear as people move among information, evaluation, services, and follow-through? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for the blood cancer referral and treatment pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Standard pre-visit test set for common hematology referral reasons | First visits used for information gathering instead of decisions | Hematology medical director with primary care lead | Share of referrals with complete pre-visit testing |
| Shared referral criteria across specialties | Inconsistent referrals and diagnostic reclassification late in the process | Hematology and primary care leadership | Published criteria and audit of referral sources |
| Tracked laboratory turnaround for specialized tests | Hidden delay in send-out pathology and molecular testing | Laboratory director | Turnaround time reported monthly by test type |
| Timely transplant and CAR T-cell referral review | Eligible patients referred late or not at all | Cellular therapy program director | Time from eligibility to evaluation, by referral source |
| Psychosocial and practical needs screening at diagnosis | Distress and logistical barriers that affect adherence go unaddressed | Nurse navigation lead | Screening completion and follow-up actions logged |
| Survivorship prompts for under-discussed needs | Common concerns never raised or addressed | Survivorship program lead | Prompt use rate in survivorship visits |
| Equity reporting for access measures | Gaps by age, distance or payer remain invisible | Chief quality officer | Access measures stratified and reviewed quarterly |
Control points derived from the cited evidence [1], [3], [4], [5], [6], [7] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating about blood cancer without adding fear or false reassurance
Awareness messages about blood cancer often focus on symptoms, yet many early signs surface first in primary care as nonspecific findings. The Tanzanian cohort and the Madrid referral study both point to the referral pathway itself as a source of delay or low-value visits.[2][1] Public messages can therefore emphasize clear routes to evaluation rather than self-diagnosis.
Clinician-to-clinician communication is part of public communication, because it shapes what patients hear next. In the Madrid initiative, the text of primary care referral notes drove automated test ordering before the specialist visit.[1] In the clonal hematopoiesis clinic, targeted sequencing often changed the working diagnosis after referral.[3] Patients need a plain explanation of why tests are ordered, what a reclassified diagnosis means and who will follow up. A consistent script for referring clinicians can reduce confusion and repeat calls.
Communication at the moment of diagnosis deserves equal care. In the study of newly diagnosed acute leukemia or lymphoma, 33% of patients reported moderate-to-severe post-traumatic stress symptoms.[6] The authors noted that these symptoms may influence treatment adherence and patient-clinician communication.[6] Teams can plan first conversations with time, written next steps and a named contact who answers practical questions.
Survivorship communication should invite topics patients may not raise. In the chronic lymphocytic leukemia survey, interest in formal counseling was limited even though most respondents reported at least one sexual function symptom.[7] The authors recommended routine clinician-initiated discussion.[7] A short, standard prompt in survivorship visits can make that discussion normal rather than awkward.
Community conversations about risk need careful framing. The French case-control study found associations between some agricultural neighborhood profiles and childhood lymphoblastic leukemia, not proof of a direct effect.[15] The Swedish cohort showed that transformation risk varies by disease subtype, age and duration.[9] Messages that respect this uncertainty build more trust than messages that overstate it.
Finally, communication about advanced therapies should be honest about access. The CAR T-cell review described high costs and complex requirements that limit availability.[5] Public materials can explain how referral to transplant or cellular therapy evaluation works, who decides and how long it usually takes in the local system. They can also name the support available for travel, lodging and caregiver time. Honest information about these steps lets patients and referring clinicians plan, rather than wait without knowing what comes next. It also gives community physicians a reason to refer early.

Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Blood Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Blood Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Month observance
Turn Blood Cancer Awareness Month into accountable action.
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Blood Cancer Awareness Month, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Blood Cancer Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Apellaniz JS, Córdoba Mascuñano R, Llamas Sillero P, Paredes Coronel C, Pfang B, Villegas García MA, et al. What factors influence patient participation in an artificial intelligence-based initiative to optimise referrals from primary to specialist haematology care? A multicentre retrospective observational study in four Spanish hospitals. BMJ Open. 2026;16(3):e115195. https://doi.org/10.1136/bmjopen-2025-115195
- 2.Philbert R, Mwamtemi H, Okade T, Mutyaba H, Ndyetabula L, Shimba E, et al. Patient pathways, presentation time, time to diagnosis, and early survival outcomes in pediatric acute lymphoblastic leukemia at Muhimbili National Hospital, Dar es Salaam, Tanzania. Frontiers in Pediatrics. 2026;14:1777603. https://doi.org/10.3389/fped.2026.1777603
- 3.Mohammad A, Iruvanti S, Marcellino BK, Nathan DI. Multispecialty referral patterns to a clonal hematopoiesis clinic: Who, what, and why?. Leukemia Research. 2026;168. https://doi.org/10.1016/j.leukres.2026.108273
- 4.de la Cruz-de la Cruz C, González-Mártinez YM, Gómez-De León A. Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies. Current Hematologic Malignancy Reports. 2026;21(1). https://doi.org/10.1007/s11899-026-00788-z
- 5.Gava F, Dwivedi A, Jain H, Schultz KR, Clé DV, Shah NN. Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India. Cytotherapy. 2026;28(9). https://doi.org/10.1016/j.jcyt.2026.102780
- 6.Guolo F, Del Sette P, Riccardi F, Ballerini F, Lemoli RM, Minetto P, et al. Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications. Leukemia & Lymphoma. 2026;67(6):1283-1289. https://doi.org/10.1080/10428194.2026.2634180
- 7.Levy Yurkovski I, Kreiniz N, Peleg-Nesher S, Koren L, Tadmor T. Sexual health and intimacy concerns among patients with chronic lymphocytic leukemia: a cross-sectional needs assessment study. Leukemia & Lymphoma. 2026;67(10):2048-2056. https://doi.org/10.1080/10428194.2026.2682282
- 8.Merrill M, Kim HT, Kelkar AH, Panaro K, Tamada R, Au C, et al. Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study. Leukemia & Lymphoma. 2026;67(7):1502-1508. https://doi.org/10.1080/10428194.2026.2645933
- 9.Batyrbekova N, Landtblom AR, Hultcrantz M, Szulkin R, Dickman PW, Andersson TM. Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study. European Journal of Haematology. 2026;116(6):850-862. https://doi.org/10.1111/ejh.70141
- 10.Neofytos D, Muñoz P, Averbuch D, Mikulska M, Vanbiervliet Y, Baccelli F, et al. Non-culture based diagnostic tests for detection of bacterial infections in hematology patients with febrile neutropenia: A review by the European Conference on Infections in Leukemia (ECIL-10). Current Research in Translational Medicine. 2026;74(3). https://doi.org/10.1016/j.retram.2026.103600
- 11.Meena JP, Makkar H, Bhattacharya S, PR RS, Gupta AK, Halder A, et al. Procalcitonin and proadrenomedullin in pediatric acute leukemia: biomarkers for infection and beyond. The Turkish Journal of Pediatrics. 2026;68(3):461. https://doi.org/10.24953/turkjpediatr.2026.6705
- 12.Moraes CRP, Saraiva CMDA, Borba-Junior IT, Duarte BKL, de Campos PM, Saad STO, et al. Plasma levels of soluble podoplanin are higher in acute promyelocytic leukemia compared to other forms of acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. 2026;48(1). https://doi.org/10.1016/j.htct.2025.106227
- 13.Demircan V, Karakuş A, Dönen SB, Ayyıldız MO. The Effect of BCR-ABL(IS) Levels on Early and Late-Stage Response Rates and Prognosis at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase. Sakarya Tıp Dergisi. 2026;16(3):392-397. https://doi.org/10.31832/smj.1938436
- 14.Elashwah S, Niazy NA, Sakr DH, El-Ashwah S, Ebrahim MA, Fahmi MW. Impact of hepatitis C virus infection and blood cell parameters on acute promyelocytic leukemia outcome: a single center experience. Egyptian Journal of Haematology. 2026;51(2):292-298. https://doi.org/10.4103/ejh.ejh_29_23
- 15.Mancini M, Faure L, Poulalhon C, Danjou A, Goujon S. Association between residential proximity to crop areas and childhood acute leukemia risk in mainland France – GEOCAP case-control study. International Journal of Hygiene and Environmental Health. 2026;272. https://doi.org/10.1016/j.ijheh.2025.114737
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Burden and long-term transformation risk in myeloproliferative neoplasms | [9] | 2026 | Current evidence | Swedish national register data; cumulative incidence estimated at one diagnosis age; may not generalize to U.S. populations. |
| Environmental exposure and childhood acute leukemia risk | [15] | 2026 | Current evidence | Observational case-control design using crop proximity as a proxy for pesticide exposure; association, not causation. |
| Laboratory markers and outcomes at diagnosis | [13] [14] | 2026 | Current evidence | Single-center retrospective studies with small samples. |
| Referral pathways and time to diagnosis | [2] | 2026 | Current evidence | Single national hospital in a low-resource setting; 64 children; descriptive design. |
| Automated pre-visit testing for hematology referrals | [1] | 2026 | Continuum of care | Retrospective observational study in four Madrid academic hospitals; only a small share of eligible patients participated. |
| Multispecialty referral patterns to a clonal hematopoiesis clinic | [3] | 2026 | Continuum of care | Retrospective chart review of 126 referrals in one academic health system. |
| Transplant outcomes and long-term follow-up needs | [8] | 2026 | Continuum of care | Single-center retrospective study of 33 patients with a rare leukemia. |
| Survivorship and sexual health needs | [7] | 2026 | Continuum of care | Cross-sectional anonymous survey of 59 patients; self-reported data. |
| Diagnostic and treatment inequities and resource-adapted strategies | [4] [5] | 2026 | Access | Narrative reviews focused on resource-constrained settings; supporting evidence largely observational. |
| Infection diagnostics and new assays in hematology | [10] [11] [12] | 2026 | Access | Expert review found limited data; biomarker studies are single-center and early-stage. |
| Psychological distress and practical needs at diagnosis | [6] | 2026 | Equity and trust | Single study of 68 patients using questionnaires at diagnosis. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

